Antidote Therapeutics Progresses Optimization of the Nicotine-degrading Enzyme, NicA2, for Potential Use in Treating Nicotine Addiction
Biospace,
GAITHERSBURG, Md.--( BUSINESS WIRE )-- Antidote Therapeutics, Inc. (ATI) announced today the publication of the successful…